**Checklist for Reporting Human Islet Preparations Used in Research**

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. Diabetologia <https://doi.org/10.1007/s00125-018-4772-2>.

|  |  |
| --- | --- |
|  | |
| **Manuscript DOI:** https://doi.org/10.2337/**[DB19-0525.R1]** | |
| **Title:Low Dose IL-2 Combined with Rapamycin Led to an Expansion of CD4+CD25+FOXP3+ Tregs and Prolonged Human Islet-allograft Survival in Humanized Mice** | |
| **Author list:** Min Hu, Wayne J Hawthorne, Leigh Nicholson, Heather Burns, Yi Wen Qian, David Liuwantara, Elvira Jimenez Vera, Yi Vee Chew, Lindy Williams, Shounan Yi, Karen Keung,Debbie Watson, Natasha Rogers, Stephen I Alexander and Philip J O’Connell | |
| **Corresponding author:** Min Hu and Philip J O’Connell | **Email address:min.hu@sydney.edu.au and philip.oconnell@sydney.edu.au** |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Islet preparation** | **17** |  |  |  |  |  |  |  |
| **MANDATORY INFORMATION** | | | | | | | | |
| Unique identifier | D19-0963 |  |  |  |  |  |  |  |
| Donor age (years) | 58 |  |  |  |  |  |  |  |
| Donor sex (M/F) | F |  |  |  |  |  |  |  |
| Donor BMI (kg/m2) | 35.16 |  |  |  |  |  |  |  |
| Donor HbA1c or other measure of blood glucose control | 5.9 |  |  |  |  |  |  |  |
| Origin/source of isletsb | Australian Islet Transplant Consortium |  |  |  |  |  |  |  |
| Islet isolation centre | WIT |  |  |  |  |  |  |  |
| Donor history of diabetes? Yes/No | No |  |  |  |  |  |  |  |
| **If Yes, complete the next two lines if this information is available** | | | | | | | | |
| Diabetes duration (years) |  |  |  |  |  |  |  |  |
| Glucose-lowering therapy at time of deathc |  |  |  |  |  |  |  |  |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **RECOMMENDED INFORMATION** | | | | | | | | |
| Donor cause of death | ICH-Subarachnoid haemmorhage |  |  |  |  |  |  |  |
| Warm ischaemia time (h) | N/A |  |  |  |  |  |  |  |
| Cold ischaemia time (h) | 7.42 |  |  |  |  |  |  |  |
| Estimated purity (%) | 80 |  |  |  |  |  |  |  |
| Estimated viability (%) | 95 |  |  |  |  |  |  |  |
| Total culture time (h)d | 82 |  |  |  |  |  |  |  |
| Glucose-stimulated insulin secretion or other functional measuremente | 1.2 |  |  |  |  |  |  |  |
| Handpicked to purity? Yes/No | No |  |  |  |  |  |  |  |
| Additional notes |  |  |  |  |  |  |  |  |

aIf you have used more than eight islet preparations, please complete additional forms as necessary

bFor example, IIDP, ECIT, Alberta IsletCore

cPlease specify the therapy/therapies

dTime of islet culture at the isolation centre, during shipment and at the receiving laboratory

ePlease specify the test and the results